If you have an upcoming diabetes trial and would like the hypoglycemic event to trigger an ePRO and then have access to this insight in near real time, please do reach out to us to learn more about GlucoseReady!
Today we announce the launch of GlucoseReady™, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy. Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance. Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. Together, GlucoseReady™ provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink